We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
275
Reports published
10k+
Readers in database
R&D KOL event externally validates the quality of @RedxPharma #MedicinalChemistry expertise in solving druggability issues. Ph I data so far confirms promising safety & PK profiles of lead internal assets RXC004 (#Cancer ) & RXC007 (#fibrosis). $REDX.L https://www.trinitydelta.org/companies/redx-pharma/
Progress on multiple fronts at #AGL. Potential Q421 catalysts include: FDA approval of @Parsortix, clinical #ovariancancer LDT data, & US/UK clinical labs accreditation driving pharma service revenues, & acting as demonstrators & accelerators. $AGL.L https://www.trinitydelta.org/companies/angle/
Foundations established for both @avacta businesses. With 1st shipments of @AvactaDx's #COVID #LFT attention now shifts to commercial execution. But Therapeutics, now clinical-stage, will be longer-term value driver. H121 cash runs thru to 2023 $AVCT.L https://www.trinitydelta.org/companies/avacta/
H121 results highlight YTD #FuturaMedical progress: MED3000 CE Mark, 3 regional partnerships, US confirmatory study start, & £12m raise extending cash runway beyond potential 2023 FDA OTC approval as an #erectiledysfunction treatment.
For more on $FUM.L https://www.trinitydelta.org/companies/futura-medical/
Stellar clinical & operational progress evidenced in @arecor_ltd's H121 results. Highlights include the #AIM #IPO, positive #AT278 Phase I #diabetes data; #AT247 FDA IND clearance; & new #formulation partnerships. For more on $AREC.L: https://www.trinitydelta.org/companies/arecor-therapeutics/
Two #AllergyTherapeutics Updates this week, following the #VLP #allergy vaccine KOL event (exploring the VLP platform & promising preclinical #PeanutAllergy data in conjunction with @ImperialMed) & report of resilient FY21 results. For more on $AGY.L : https://www.trinitydelta.org/companies/allergy-therapeutics/
Please sign up here to be added to our distribution database
';